Publieke consultatie EMA 'Draft Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies' geopend
Het European Medicines Agency (EMA) heeft een publieke consultatie geopend met betrekking tot de 'Draft Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies'.
End of consultation (deadline for comments) 10 april 2023. |